NMTC

+ Watchlist + Portfolio

NeuroOne Medical Technologies Corp.

Regulated industry Physical products Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.99
52-Week Range: $0.96 – $6.96
Market Cap: $10.20M
P/E (TTM): —
EPS (TTM): -0.99
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 2.59
PEG Ratio: —
Return on Equity: -124.66%
Return on Assets: -58.07%
Gross Margin: 23.00%
Operating Margin: -122.87%
Profit Margin: -59.71%
Current Ratio: 2.84
Debt/Equity: 0.05
Total Debt: $175.34K
Free Cash Flow: $-4.57M
Revenue Growth: 16.30%
Earnings Growth: —
Enterprise Value: $8.33M

NMTC Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$171.17K	$1.95M	$3.45M	$9.10M
Cost of Revenue	$241.96K	$1.50M	$2.37M	$3.96M
Gross Profit	-$70.79K	$456.52K	$1.08M	$5.14M
Research & Development	$4.93M	$6.94M	$5.07M	$4.98M
Selling, General & Admin	$6.98M	$6.93M	$7.90M	$7.38M
Operating Expenses	$9.96M	$12.41M	$12.97M	$9.37M
Operating Income	-$10.03M	-$11.96M	-$11.89M	-$4.23M
EBITDA	-$9.91M	-$11.66M	-$11.84M	-$3.01M
Pretax Income	-$10.00M	-$11.86M	-$12.32M	-$3.61M
Income Tax	$0.00	$0.00	$0.00	$0.00
Net Income	-$10.00M	-$11.86M	-$12.32M	-$3.61M
Diluted EPS	-3.78	-3.90	-2.76	-0.54
Diluted Shares	2.67M	3.02M	4.46M	6.69M

NMTC Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$8.16M	$5.32M	$1.46M	$6.57M
Receivables	$33.24K	$0.00	$176.64K	$1.26M
Inventory	$704.54K	$1.73M	$2.64M	$2.23M
Current Assets	$12.18M	$7.31M	$4.63M	$10.23M
Total Assets	$12.82M	$8.10M	$5.37M	$10.79M
Current Liabilities	$3.10M	$1.79M	$2.21M	$2.30M
Total Debt	$202.90K	$184.40K	$260.16K	$266.81K
Total Liabilities	$3.22M	$1.85M	$4.55M	$3.71M
Retained Earnings	-$50.83M	-$62.69M	-$75.00M	-$78.61M
Shareholders' Equity	$9.60M	$6.25M	$822.01K	$7.07M
Working Capital	$9.08M	$5.52M	$2.42M	$7.92M

NMTC Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$7.52M	-$12.89M	-$11.01M	-$2.84M
Capital Expenditure	-$275.23K	-$384.12K	-$120.20K	-$81.74K
Free Cash Flow	-$7.79M	-$13.27M	-$11.13M	-$2.92M
Depreciation & Amortisation	$118.62K	$199.27K	$246.79K	$261.68K
Stock-Based Compensation	$947.21K	$1.11M	$1.34M	$1.26M
Investing Cash Flow	-$3.24M	$2.65M	-$120.20K	-$81.74K
Financing Cash Flow	$12.02M	$7.40M	$7.27M	$8.03M
Share Repurchases	$0.00	-$119.42K	-$81.40K	-$124.62K
Net Change in Cash	$1.26M	-$2.84M	-$3.86M	$5.11M

NMTC Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$1.39M	$1.70M	$2.74M	$2.89M	$1.86M	$1.97M
Cost of Revenue	$615.49K	$781.22K	$1.21M	$1.32M	$871.79K	$790.50K
Gross Profit	$771.06K	$914.84K	$1.53M	$1.57M	$990.26K	$1.18M
Research & Development	$1.51M	$1.18M	$1.12M	$1.39M	$1.47M	$1.43M
Selling, General & Admin	$1.94M	$1.62M	$1.78M	$1.89M	$1.92M	$2.18M
Operating Expenses	$3.45M	$2.80M	$2.90M	$3.28M	$3.39M	$3.61M
Operating Income	-$2.68M	-$1.89M	-$1.37M	-$1.71M	-$2.40M	-$2.42M
EBITDA	-$2.20M	-$1.42M	-$1.55M	-$1.37M	-$2.32M	-$1.96M
Pretax Income	-$2.27M	-$1.50M	-$1.62M	-$1.44M	-$2.38M	-$2.01M
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	-$2.27M	-$1.50M	-$1.62M	-$1.44M	-$2.38M	-$2.01M
Diluted EPS	-0.42	-0.19	—	-0.18	-0.28	-0.23
Diluted Shares	5.19M	8.10M	—	8.39M	8.48M	8.74M

NMTC Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$1.32M	$8.04M	$6.57M	$3.56M	$2.80M	$2.05M
Receivables	$318.78K	$0.00	$1.26M	$2.66M	$2.43M	$1.10M
Inventory	$1.83M	$1.90M	$2.23M	$1.67M	$1.87M	$2.29M
Current Assets	$3.75M	$10.17M	$10.23M	$8.07M	$7.40M	$5.79M
Total Assets	$4.46M	$10.82M	$10.79M	$8.58M	$7.86M	$6.19M
Current Liabilities	$1.76M	$1.43M	$2.30M	$1.26M	$1.69M	$2.04M
Total Debt	$311.41K	$295.72K	$266.81K	$237.38K	$206.97K	$175.34K
Total Liabilities	$3.33M	$2.64M	$3.71M	$2.18M	$2.49M	$2.42M
Retained Earnings	-$75.49M	-$76.99M	-$78.61M	-$80.05M	-$82.13M	-$84.44M
Shareholders' Equity	$1.13M	$8.18M	$7.07M	$6.40M	$5.37M	$3.77M
Working Capital	$1.99M	$8.74M	$7.92M	$6.81M	$5.71M	$3.75M

NMTC Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$56.14K	-$1.46M	-$1.53M	-$3.12M	-$1.33M	-$1.08M
Capital Expenditure	-$3.17K	-$43.55K	-$10.61K	-$40.75K	-$38.52K	-$19.66K
Free Cash Flow	-$59.31K	-$1.51M	-$1.54M	-$3.16M	-$1.37M	-$1.10M
Depreciation & Amortisation	$65.63K	$66.59K	$64.32K	$65.52K	$60.03K	$47.00K
Stock-Based Compensation	$250.17K	$316.65K	$358.56K	$359.25K	$342.13K	$352.78K
Investing Cash Flow	-$3.17K	-$43.55K	-$10.61K	-$40.75K	-$38.52K	-$19.66K
Financing Cash Flow	$245.22K	$8.23M	$66.98K	$147.82K	$609.62K	$345.03K
Share Repurchases	-$107.11K	-$3.47K	-$2.77K	-$3.63K	-$60.78K	-$3.18K
Net Change in Cash	$185.90K	$6.72M	-$1.47M	-$3.01M	-$757.61K	-$756.41K

Market Snapshot

About

NeuroOne Medical Technologies Corp. develops minimally invasive medical devices for brain monitoring, diagnosis, and treatment of neurological conditions.